Singapore-based precision gut microbiome company AMILI has snapped up $10.5 million in a Series A funding round led by technology and life sciences investor Vulcan Capital.
New investors also joined the round, including Pruksa Group, TVM Capital Healthcare, Emtek Group, Capital Code, Pureland Group, Blue7 and Enterprise Singapore's investment arm SEEDS Capital.
WHAT IT DOES
Founded in 2019, the...
